Clinical trial
A Multicenter Randomized Controlled Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors
NCT05784870 is registered in ClinicalTrials.gov with Zhongnan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Randomized Controlled Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors
- Lead sponsor
- Zhongnan Hospital
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- February 7, 2023
- Completion date
- December 31, 2024
- Enrollment
- 168 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cancer-related anemia, hematological malignancy